Switch to:
AbbVie Inc (NYSE:ABBV)
Research and Development
$3,402 Mil (TTM As of Jun. 2014)

This is the expense the company spent on research and development. AbbVie Inc's research and development for the three months ended in Jun. 2014 was $850 Mil. Its research and development for the trailing twelve months (TTM) ended in Jun. 2014 was $3,402 Mil.


Definition

This is the expense the company spent on research and development.

AbbVie Inc Research & Development for the trailing twelve months (TTM) ended in Jun. 2014 was 934 (Sep. 2013 ) + 846 (Dec. 2013 ) + 772 (Mar. 2014 ) + 850 (Jun. 2014 ) = $3,402 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

AbbVie Inc Annual Data

Dec09Dec10Dec11Dec12Dec13
Research & Development 000001,7072,8082,6183,0663,193

AbbVie Inc Quarterly Data

Mar12Jun12Sep12Dec12Mar13Jun13Sep13Dec13Mar14Jun14
Research & Development 642642813969634779934846772850
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK